Please login to the form below

Not currently logged in
Email:
Password:

Eisai cuts US workforce by 20 percent

Eisai, the US pharmaceutical operation of Japan's Eisai, plans to cut its workforce by about 20 per cent across all US functions

Eisai, the US pharmaceutical operation of Japan's Eisai, plans to cut its workforce by about 20 per cent across all US functions, laying off approximately 600 workers by the start of next month.

"This organisational restructuring supports Eisai's global mid-term strategic plan for FY2011-2015, which seeks to transform Eisai's business into a more efficient and focused organisation to better serve its human healthcare mission," says the company.

Eisai intends to invest the cost-savings largely in accelerating its oncology portfolio and launching new neuroscience assets.

Eisai said it does not plan to close any of its main offices or facilities. The company's US operations include R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina.

The announcement of the layoffs comes on the heels of Eisai's decision last month to delay the submission of US, European and Japanese marketing applications for its investigational sepsis drug eritoran due to disappointing preliminary results from a global phase III trial. The company had been aiming to submit the applications by March 31, but a preliminary analysis of data showed the drug was not effective in reducing 28-day all-cause mortality in patients with severe sepsis.

The company is also struggling to replace profits lost when the blockbuster Alzheimer's disease drug Aricept (donepezil) lost its patent protection late last year.

9th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...